Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VIB4920 in Sjögren's Syndrome
2019-002713-19Phase 2Unknown
- Sponsor
- Viela Bio
- Start
- Nov 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome comparing VIB4920 with Placebo (2 arms). Primary endpoint: Primary efficacy and safety endpoints. Status: unknown.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2019-002713-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002713-19.